Vivek Subbiah, MD, MD Anderson Cancer Center
Advertisement
Articles by Vivek Subbiah, MD, MD Anderson Cancer Center
Advertisement
Latest Updated Articles
Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLCPublished: September 5th 2020 | Updated:
Future Directions in Treatment of Small Cell Lung CancerPublished: August 26th 2021 | Updated:
Emerging Treatments in SCLC: Impact of Targeted TherapyPublished: August 26th 2021 | Updated:
SCLC: Second-Line Options and Supportive CarePublished: August 5th 2021 | Updated:
Dr. Subbiah on the Utility of Tivozanib in RCCPublished: May 20th 2020 | Updated:
Dr. Subbiah on Safety and Efficacy of BLU-667 in RET-Altered Solid TumorsPublished: April 16th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5